PAR 3.92% 24.5¢ paradigm biopharmaceuticals limited..

research reports and media, page-2867

  1. 327 Posts.
    lightbulb Created with Sketch. 49
    Looks like Kolon life science who is developing Invossa got a smack on the hand for misleading information about there product, and whats in it and the source of it.I wouldn't imagine this would sit very well with the FDA especially if it was intentional.
    If interested search(Kolon CEO arrested for mislabelling Invossa's ingredient).
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
24.5¢
Change
-0.010(3.92%)
Mkt cap ! $85.70M
Open High Low Value Volume
24.5¢ 25.0¢ 24.0¢ $59.66K 241.2K

Buyers (Bids)

No. Vol. Price($)
4 78837 24.5¢
 

Sellers (Offers)

Price($) Vol. No.
25.0¢ 36290 1
View Market Depth
Last trade - 16.10pm 30/08/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.